Acute kidney injury in patients receiving pembrolizumab combination therapy versus pembrolizumab monotherapy for advanced lung cancer

ICPi-AKI Consortium

doi:10.1016/j.kint.2022.07.019

Acute kidney injury in patients receiving pembrolizumab combination therapy versus pembrolizumab monotherapy for advanced lung cancer

ICPi-AKI Consortium

Research output: Contribution to journal › Article › peer-review

Original language	English (US)
Pages (from-to)	930-935
Number of pages	6
Journal	Kidney international
Volume	102
Issue number	4
DOIs	https://doi.org/10.1016/j.kint.2022.07.019
State	Published - Oct 2022

Funding

SG receives research funding from GE Healthcare and BTG International and is president and founder of the American Society of Onconephrology. KDJ is a consultant for Astex Pharmaceuticals, Natera, GlaxoSmithKline, ChemoCentryx, and Chinook; a paid contributor to Uptodate.com; receives honorarium from the International Society of Nephrology and the American Society of Nephrology; and is cofounder and copresident of the American Society of Onconephrology. DSS participates in the speakers’ bureau at Genentech. FBC is a consultant for ChemoCentryx and Retrophin. AA is supported by the Division of Internal Medicine Immuno-Oncology Toxicity Award Program of the University of Texas MD Anderson Cancer Center. BS is a senior clinical investigator at the Research Foundation Flanders (F.W.O.) (1842919N) and is supported by Stichting tegen Kanker (grant C/2020/1380). AR is a consultant for Otsuka Pharmaceutical Company and treasurer of the American Society of Onconephrology. SMH is supported by the Mayo Clinic K2R award. KB receives grant support from the Olympia Morata Programme, Foundations Commission of University of Heidelberg, Rheumaliga Baden-Württemberg e.V., Abbvie, and Novartis; and also serves as a consultant for and receives speaker fee/travel reimbursements from Abbvie, BMS, Janssen, MSD, Viatris, Gilead/Galapagos, Janssen, Lilly, Medac, Mundipharma, Novartis, Pfizer, Roche, and Union Chimique Belge. MES has served on a scientific advisory board for Mallinckrodt. MJM has served as a consultant or received honorarium from AstraZeneca, Immunai, Istari Oncology, Nektar Therapeutics, and Bristol Myers Squibb. LC serves as a consultant for and receives honorarium and/or travel reimbursements from Pfizer, Bristol Myers Squibb, and MSD. All other authors declared no competing interests.

ASJC Scopus subject areas

Nephrology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.kint.2022.07.019

Cite this

@article{f3971b032e3140489608bbe70449b2d9,

title = "Acute kidney injury in patients receiving pembrolizumab combination therapy versus pembrolizumab monotherapy for advanced lung cancer",

author = "{ICPi-AKI Consortium} and Shruti Gupta and Strohbehn, {Ian A.} and Qiyu Wang and Hanna, {Paul E.} and Rituvanthikaa Seethapathy and Prosek, {Jason M.} and Herrmann, {Sandra M.} and Ala Abudayyeh and Malik, {A. Bilal} and Sebastian Loew and Carlos, {Christopher A.} and Chang, {Wei Ting} and Pazit Beckerman and Zain Mithani and Shah, {Chintan V.} and Renaghan, {Amanda D.} and {de Seigneux}, Sophie and Luca Campedel and Abhijat Kitchlu and Shin, {Daniel Sanghoon} and Gaia Coppock and Nuttha Lumlertgul and Pablo Garcia and Ortiz-Melo, {David I.} and Arash Rashidi and Ben Sprangers and Vikram Aggarwal and Karolina Benesova and Jhaveri, {Kenar D.} and Cortazar, {Frank B.} and Astrid Weins and Yiqin Zuo and Mooradian, {Meghan J.} and Reynolds, {Kerry L.} and Leaf, {David E.} and Sise, {Meghan E.} and Salem, {Joe Elie} and Bagnis, {Corinne Isnard} and Harkarandeep Singh and Motwani, {Shveta S.} and Naoka Murakami and Tio, {Maria C.} and Mothi, {Suraj S.} and Umut Selamet and Schmidt-Ott, {Kai M.} and Weiting Chang and Rimda Wanchoo and Yuriy Khanin and Hirsch, {Jamie S.} and Sunandana Chandra",

note = "Funding Information: SG receives research funding from GE Healthcare and BTG International and is president and founder of the American Society of Onconephrology. KDJ is a consultant for Astex Pharmaceuticals, Natera, GlaxoSmithKline, ChemoCentryx, and Chinook; a paid contributor to Uptodate.com; receives honorarium from the International Society of Nephrology and the American Society of Nephrology; and is cofounder and copresident of the American Society of Onconephrology. DSS participates in the speakers{\textquoteright} bureau at Genentech. FBC is a consultant for ChemoCentryx and Retrophin. AA is supported by the Division of Internal Medicine Immuno-Oncology Toxicity Award Program of the University of Texas MD Anderson Cancer Center. BS is a senior clinical investigator at the Research Foundation Flanders (F.W.O.) (1842919N) and is supported by Stichting tegen Kanker (grant C/2020/1380). AR is a consultant for Otsuka Pharmaceutical Company and treasurer of the American Society of Onconephrology. SMH is supported by the Mayo Clinic K2R award. KB receives grant support from the Olympia Morata Programme, Foundations Commission of University of Heidelberg, Rheumaliga Baden-W{\"u}rttemberg e.V., Abbvie, and Novartis; and also serves as a consultant for and receives speaker fee/travel reimbursements from Abbvie, BMS, Janssen, MSD, Viatris, Gilead/Galapagos, Janssen, Lilly, Medac, Mundipharma, Novartis, Pfizer, Roche, and Union Chimique Belge. MES has served on a scientific advisory board for Mallinckrodt. MJM has served as a consultant or received honorarium from AstraZeneca, Immunai, Istari Oncology, Nektar Therapeutics, and Bristol Myers Squibb. LC serves as a consultant for and receives honorarium and/or travel reimbursements from Pfizer, Bristol Myers Squibb, and MSD. All other authors declared no competing interests. ",

year = "2022",

month = oct,

doi = "10.1016/j.kint.2022.07.019",

language = "English (US)",

volume = "102",

pages = "930--935",

journal = "Kidney international",

issn = "0085-2538",

publisher = "Elsevier B.V.",

number = "4",

}

TY - JOUR

T1 - Acute kidney injury in patients receiving pembrolizumab combination therapy versus pembrolizumab monotherapy for advanced lung cancer

AU - ICPi-AKI Consortium

AU - Gupta, Shruti

AU - Strohbehn, Ian A.

AU - Wang, Qiyu

AU - Hanna, Paul E.

AU - Seethapathy, Rituvanthikaa

AU - Prosek, Jason M.

AU - Herrmann, Sandra M.

AU - Abudayyeh, Ala

AU - Malik, A. Bilal

AU - Loew, Sebastian

AU - Carlos, Christopher A.

AU - Chang, Wei Ting

AU - Beckerman, Pazit

AU - Mithani, Zain

AU - Shah, Chintan V.

AU - Renaghan, Amanda D.

AU - de Seigneux, Sophie

AU - Campedel, Luca

AU - Kitchlu, Abhijat

AU - Shin, Daniel Sanghoon

AU - Coppock, Gaia

AU - Lumlertgul, Nuttha

AU - Garcia, Pablo

AU - Ortiz-Melo, David I.

AU - Rashidi, Arash

AU - Sprangers, Ben

AU - Aggarwal, Vikram

AU - Benesova, Karolina

AU - Jhaveri, Kenar D.

AU - Cortazar, Frank B.

AU - Weins, Astrid

AU - Zuo, Yiqin

AU - Mooradian, Meghan J.

AU - Reynolds, Kerry L.

AU - Leaf, David E.

AU - Sise, Meghan E.

AU - Salem, Joe Elie

AU - Bagnis, Corinne Isnard

AU - Singh, Harkarandeep

AU - Motwani, Shveta S.

AU - Murakami, Naoka

AU - Tio, Maria C.

AU - Mothi, Suraj S.

AU - Selamet, Umut

AU - Schmidt-Ott, Kai M.

AU - Chang, Weiting

AU - Wanchoo, Rimda

AU - Khanin, Yuriy

AU - Hirsch, Jamie S.

AU - Chandra, Sunandana

N1 - Funding Information: SG receives research funding from GE Healthcare and BTG International and is president and founder of the American Society of Onconephrology. KDJ is a consultant for Astex Pharmaceuticals, Natera, GlaxoSmithKline, ChemoCentryx, and Chinook; a paid contributor to Uptodate.com; receives honorarium from the International Society of Nephrology and the American Society of Nephrology; and is cofounder and copresident of the American Society of Onconephrology. DSS participates in the speakers’ bureau at Genentech. FBC is a consultant for ChemoCentryx and Retrophin. AA is supported by the Division of Internal Medicine Immuno-Oncology Toxicity Award Program of the University of Texas MD Anderson Cancer Center. BS is a senior clinical investigator at the Research Foundation Flanders (F.W.O.) (1842919N) and is supported by Stichting tegen Kanker (grant C/2020/1380). AR is a consultant for Otsuka Pharmaceutical Company and treasurer of the American Society of Onconephrology. SMH is supported by the Mayo Clinic K2R award. KB receives grant support from the Olympia Morata Programme, Foundations Commission of University of Heidelberg, Rheumaliga Baden-Württemberg e.V., Abbvie, and Novartis; and also serves as a consultant for and receives speaker fee/travel reimbursements from Abbvie, BMS, Janssen, MSD, Viatris, Gilead/Galapagos, Janssen, Lilly, Medac, Mundipharma, Novartis, Pfizer, Roche, and Union Chimique Belge. MES has served on a scientific advisory board for Mallinckrodt. MJM has served as a consultant or received honorarium from AstraZeneca, Immunai, Istari Oncology, Nektar Therapeutics, and Bristol Myers Squibb. LC serves as a consultant for and receives honorarium and/or travel reimbursements from Pfizer, Bristol Myers Squibb, and MSD. All other authors declared no competing interests.

PY - 2022/10

Y1 - 2022/10

UR - http://www.scopus.com/inward/record.url?scp=85136628168&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85136628168&partnerID=8YFLogxK

U2 - 10.1016/j.kint.2022.07.019

DO - 10.1016/j.kint.2022.07.019

M3 - Article

C2 - 35964800

AN - SCOPUS:85136628168

SN - 0085-2538

VL - 102

SP - 930

EP - 935

JO - Kidney international

JF - Kidney international

IS - 4

ER -

Acute kidney injury in patients receiving pembrolizumab combination therapy versus pembrolizumab monotherapy for advanced lung cancer

Funding

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Cite this